Kenvue Inc. (KVUE)

NYSE: KVUE · IEX Real-Time Price · USD
-0.02 (-0.08%)
Jun 2, 2023, 10:42 AM EDT - Market open

Company Description

Kenvue is the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021.

We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day.

Our differentiated portfolio of iconic brands—including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette—is built for moments that uniquely matter to our consumers and, we believe, drives positive health outcomes around the world.

We are a global leader at the intersection of healthcare and consumer goods, with a portfolio of iconic brands, operating in some of the most attractive categories in consumer health from both a growth and profitability perspective.

Our consumer health portfolio includes self care, skin care and beauty and essential personal care products, which reflect categories that we believe allow consumers across the world to realize the extraordinary power of everyday care.

Kenvue Inc.
Kenvue logo
Country United States
IPO Date May 4, 2023
Industry Household & Personal Products
Sector Consumer Staples
Employees 22,200
CEO Thibaut Mongon

Contact Details

199 Grandview Road
Skillman, NJ 08558
United States
Phone (908) 874-1200

Stock Details

Ticker Symbol KVUE
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
IPO Price $22.00
CIK Code 0001944048
Employer ID 88-1032011
SIC Code 2844

Key Executives

Name Position
Thibaut Mongon Chief Executive Officer and Director
Paul Ruh Chief Financial Officer
Luani Alvarado Chief People Officer
Carlton Lawson Group President, Europe, Middle East and Africa
Donna Lorenson Chief Corporate Affairs Officer
Jan Meurer Chief Growth Officer
Matthew Orlando General Counsel
Meredith (Meri) Stevens Chief Operations Officer
Bernardo Tavares Chief Data & Technology Officer
Caroline Tillett Chief Scientific Officer

Latest SEC Filings

Date Type Title
May 8, 2023 S-8 Securities to be offered to employees in employee benefit plans
May 8, 2023 8-K Current Report
May 4, 2023 424B4 Prospectus
May 3, 2023 EFFECT Notice of Effectiveness
May 3, 2023 S-1MEF Registration adding securities to prior Form S-1 registration
May 3, 2023 CERT Certification by an exchange approving securities for listing
May 3, 2023 8-A12B Registration of securities
May 1, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 24, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 30, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933